Почетна › Немалоклетни карцином плућа › Kalifornija › Torrance
Kliničke studije za Немалоклетни карцином плућа u gradu Torrance, CA
12 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Torrance i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Тражи се учесникФаза 3
- Torrance Memorial Physician Network - Cancer Care, Torrance
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- UCLA Hematology/Oncology - Torrance, Torrance
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Тражи се учесникФаза 3
- Torrance Memorial Physician Network - Cancer Care, Torrance
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Тражи се учесникФаза 2
- City of Hope South Bay, Torrance
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Torrance Memorial Physician Network - Cancer Care, Torrance
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2/3
- City of Hope South Bay, Torrance
- Torrance Memorial Physician Network - Cancer Care, Torrance
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- Cancer and Blood Specialty Clinic, Torrance
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Тражи се учесникОпсервациона студија
- Torrance Memorial Physician Network-Cancer Care, Torrance
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Тражи се учесникФаза 3
- Clinical Study Site, Torrance
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Тражи се учесникФаза 1
- Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC, Torrance
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Тражи се учесникФаза 1
- Cancer AND Blood Specialty Clinic, Torrance
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Torrance Memorial Physician Network - Cancer Care, Torrance
Studije za Немалоклетни карцином плућа u drugim gradovima
- Houston, TX143 студија
- New York City, NY123 студија
- Arlington, VA111 студија
- Nashville, TN97 студија
- Los Angeles, CA92 студија
- Boston, MA87 студија
- St. Louis, MO68 студија
- Baltimore, MD60 студија
- San Antonio, TX60 студија
- Chicago, IL59 студија
- Columbus, OH57 студија
- Seattle, WA55 студија
Ostale studije u gradu Torrance
- Рак дојке11 студија
- Рак бешике8 студија
- Гојазност8 студија
- Гојазност8 студија
- Кардиоваскуларне болести7 студија
- Шизофренија7 студија
- Рак плућа7 студија
- Метастатски карцином6 студија
- Коронарна болест срца4 студија
- Затајење срца4 студија
- Dijabetes tipa 24 студија
- Колоректални карцином4 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.